Previous 10 | Next 10 |
home / stock / tbpmf / tbpmf news
CAUMZ targeting survival indications in advanced incurable cancer. Eligible for Fast Track designation and Accelerated Approval regulatory program. 505(b)(2) NDA pathway provides significant cost savings. OTTAWA, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma ...
QIXLEEF global market is expanded to include noncancer pain indications. Scientific approach to quality control of QIXLEEF validated by FDA. OTTAWA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in canna...
Tetra Bio-Pharma Inc. Announces Listing of Warrants Canada NewsWire ORLEANS, ON, Feb. 20, 2020 ORLEANS, ON , Feb. 20, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc . (" Tetra " or the " Corporation ") (TSXV: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based ...
A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary setting Trial expected to be completed by April 30, 2020 OTTAWA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc ., (“ Tetra ” or the “ Company ”) a leader ...
OTTAWA, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Tetra Bio Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB: TBPMF) a leader in cannabinoid-derived drug discovery and development, is pleased to announce the appointment of Sylvain Chrétien as President of T...
Agreement secures a 2D patented printing technology that will significantly boost production capacity and reduce production costs Further protects CAUMZ™ and HCC011 with four additional manufacturing patents OTTAWA, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Tetra Bio Pharma Inc. (...
Tetra Bio-Pharma Announces Closing of Bought Deal Financing Canada NewsWire OTTAWA, Feb. 13, 2020 /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES / OTTAWA , Feb. 13, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc. (" Te...
Image Source: Analytical Cannabis Company Thesis Tetra Bio Pharma ( OTCQB:TBPMF ) is one of the first companies in the marijuana industry to study the potential effects of analgesia with cannabinoids. Currently, TBMPF's leading clinical trials involves CAUMZ and QIXLEEF (9.5% Dry Pellet TH...
Tetra Bio-Pharma (TSXV: TBP ,OTCQB:TBPMF) has stepped closer to receiving fast track designation from the US Food and Drug Administration (FDA) for its drug-device combination, which aims to treat patients with incurable malignant cancer. Monday’s (February 3) announcement follows a...
Tetra Bio-Pharma Receives Favorable Response Following Type B Meeting with USA FDA for CAUMZ™ Canada NewsWire OTTAWA, Jan. 31, 2020 OTTAWA , Jan. 31, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc . (" Tetra " or the " Company ") (TSXV: TBP) (OTCQB: TBPMF), a leade...
News, Short Squeeze, Breakout and More Instantly...
Tetra Bio-Pharma Inc Company Name:
TBPMF Stock Symbol:
OTCMKTS Market:
Tetra Bio-Pharma Inc Website:
(TheNewswire) Montreal – TheNewswire - August 1, 2023 – Tetra Bio-Pharma Inc. (“ Tetra ” or the “ Company ”) ( TSX:TBP ) ( OTC:TBPMF ) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development announced that...
(TheNewswire) MONTREAL, QUEBEC – TheNewswire – May 11, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTC:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, today announced it has cancelled its New Drug Subm...
(TheNewswire) Montreal, QC - TheNewswire - March 10, 2023 - Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX:TBP) (OTC:TBPMF) (FRA:JAM1) , a leader in cannabinoid-derived drug discovery and development is pleased to announce Health Canada h...